Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Tuberous Sclerosis Complex-associated Refractory Seizures 1Gliosarcoma 1Glioma 1Glioblastoma 1Epilepsy 1Drug Resistant Epilepsy 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 15Radiotherapy 13antineoplaston AS 2-1 8antineoplaston A10 8Everolimus 7Radiation 6Erlotinib Hydrochloride 6Radiotherapy, Intensity-Modulated 5Lomustine 4veliparib 3palbociclib 3Vorinostat 3Sunitinib 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Carmustine 3Carboplatin 3temsirolimus 2selinexor 2poly ICLC 2etoposide phosphate 2cabozantinib 2Sirolimus 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Imatinib Mesylate 2Etoposide 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Astrocytoma × Anticonvulsants × Clear all
NCT00045708 2017-10-18

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

National Cancer Institute (NCI)

Phase 1/2 Completed
57 enrolled 18 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡